Senate committee approves pharmacy rule rewrite but strips disputed compounding labeling lines

The Senate Health and Welfare Committee on a roll call vote approved the Idaho State Board of Pharmacy’s pending rule chapter rewrite (docket 24-3601-2402) while striking three disputed labeling subsections that govern distribution of compounded drug products.

The committee first took no action on a temporary rule docket (24-3601-2401), as presented by Nikki Chopsky, bureau chief for health professions at the Division of Occupational and Professional Licenses and executive officer for the Idaho State Board of Pharmacy. Chopsky told the committee the temporary chapter was published after passage of House Bill 527 and was intended to avoid duplicating statute in rule; she asked the committee to let the temporary rules lapse and handle the clean, pending rewrite instead. "This uncluttered rule chapter then served as the basis of the board's ZBR efforts," Chopsky said during her overview.

The pending rewrite consolidated definitions, moved provisions now in statute out of rule, and reorganized sections on licensure, practice standards, discipline, fees and compounding. Chopsky said the board held five open public meetings, two negotiated-rulemaking hearings and one public hearing and that representatives from both state pharmacy associations and other stakeholders participated; she described attendance in some meetings as "maybe 12 to 15 people in the room and maybe as many as 20 online." She also told the committee the board removed an "incomplete list" after stakeholder feedback and did not intend the temporary rules to remain in force.

Senators focused most discussion on compounding and the distribution- labeling language in what is listed in the redline as rule 40605 (moved into new rule text at 214(e) in the pending draft). Senator Lenny warned that strict state enforcement could reduce access and raise costs if federal oversight remains flexible, using an analogy that the committee later described as meant to illustrate the trade-offs between stricter and looser enforcement. "I think it could be viewed that way," Chopsky replied to Lenny, saying Idaho has legal pathways for compounded products and in-state compounders remain available.

Senator Wintrow emphasized public safety concerns and urged the committee to retain language until stakeholders and legal uncertainties are resolved. "We're talking about drugs and the importance of making sure there is... safe dispensing," she said.

Senator Lenny then offered a substitute motion to approve the pending docket while striking subsections 214 E(i) and 214 E(ii). The committee took a roll call vote called by the secretary; the chair recorded the result as "the yeas have it" and the motion passed, 7–2. The chair summarized: "That's 7 yes and 2 no. So we've approved docket 24-3601-2402 with the exception of the E, I and II."

Chopsky told the committee the board had weighed stakeholder concerns, federal draft guidance (which she said is nonbinding), and litigation risks in deciding language. She said the board had not incorporated the FDA draft guidance and was cautious because other states that adopted draft federal guidance faced legal challenges. "The draft guidance document ... is clearly marked draft, not for implementation and contains non binding recommendations," she said. She added the board remains willing to work with stakeholders to seek a solution if federal guidance changes.

What this means: the pending rule chapter will move forward as approved by the committee but without the three labeled subsections the committee struck; the temporary chapter was allowed to expire by the committee's earlier “no action” vote. The committee’s action reflects a mixture of regulatory cleanup and a narrow policy change requested by members who expressed concern about access and federal-state alignment.

Votes at a glance

- Motion to take no action on temporary docket 24-3601-2401 (Board of Pharmacy): moved by Senator Harris; voice vote; result: no action taken (committee allowed temporary docket to expire).

- Motion to approve pending docket 24-3601-2402 (Board of Pharmacy), as amended to strike subsections 214 E(i) and 214 E(ii): substitute motion by Senator Lenny; seconded by Senator Seiderfeld; roll call vote result: 7 yeas, 2 nays; outcome: approved with those subsections removed.

Key context

- Docket numbers and affected rule chapter: IDAPA 24.36.01 (Idaho State Board of Pharmacy); pending rewrite appears in the legislative review book pages cited by Chopsky. - Stakeholder engagement: Chopsky said multiple stakeholder groups participated across five open public board meetings, two negotiated-rulemaking hearings and one public hearing; she said at times 12–15 people attended in person and as many as 20 attended online. - Legal context: Chopsky referenced House Bill 527 as the statutory change that prompted relocation of provisions to statute and said board staff reviewed federal guidance and litigation affecting compounding law but did not incorporate FDA draft guidance into Idaho rule.

Unresolved/technical notes

- The three subsections struck by the committee (listed in the redline as 214 E(i) and 214 E(ii)) were described by some stakeholders as related to labeling and distribution of compounded products; the committee vote removed those lines from the pending rule chapter. The committee record shows members debated trade-offs between access and safety and whether to rely on federal standards, but the committee did not adopt new alternative labeling language on the floor.

Sources: Committee hearing transcript, Senate Health and Welfare Committee; presentation by Nikki Chopsky, Bureau Chief, Health Professions, Division of Occupational and Professional Licenses.